TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28975543

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine injection (accelerated schedule)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Hepatitis B recombinant DNA vaccine (conventional schedule)
Number of subjects: 202
Study: 25880756

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg QD
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1600 mg QD
Number of subjects: 172

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 172
Study: 23718748

Group type: EXPERIMENTAL
Intervention: Glyburide (n=32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Insulin (n=32)
Number of subjects: 64
Study: 21262871

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 18937965

Group type: EXPERIMENTAL
Intervention: Oral irreversible P2Y12 receptor antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reversible P2Y12 receptor antagonists
Number of subjects: 0
Study: 17932898

Group type: EXPERIMENTAL
Intervention: Slow-release 17-beta estradiol-eluting R-Stent
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Moderate-release 17-beta estradiol-eluting R-Stent
Number of subjects: 95

Group type: COMPARATOR
Intervention: Bare metal stent (control)
Number of subjects: 95
Study: 15525860

Group type: EXPERIMENTAL
Intervention: Watchful Waiting Intervention (WWI) - 5 weekly intervention calls from a nurse
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 41
Study: 11575336

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg(‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9648974

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 1749
Study: 8116135

Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 243

Group type: COMPARATOR
Intervention: goserelin
Number of subjects: 243
Study: 2752179

Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-dose intravenous gamma-globulin (400 mg/kg on days 1 through 5)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of oral prednisone and high-dose intravenous gamma-globulin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 165913

Group type: EXPERIMENTAL
Intervention: ethinyl oestradiol 20 mug daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ethinyl oestradiol 50 mug daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: conjugated equine oestrogens (Premarin) 0.625 mg daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: conjugated equine oestrogens (Premarin) 1.25 mg daily
Number of subjects: 17
Study: 30858635

Group type: EXPERIMENTAL
Intervention: ECT + iv. ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: ECT + iv. placebo (midazolam)
Number of subjects: 12
Study: 26537980

Group type: EXPERIMENTAL
Intervention: Managing Cancer Care: A Personal Guide (MCC) intervention
Number of subjects: 105
Study: 26149210

Group type: EXPERIMENTAL
Intervention: 1.8 mL articaine (4% with 1:100,000 epinephrine)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 3.6 mL articaine (4% with 1:100,000 epinephrine)
Number of subjects: 82
Study: 23176311

Group type: EXPERIMENTAL
Intervention: Processed residual CPB volume
Number of subjects: 197

Group type: COMPARATOR
Intervention: Unprocessed residual CPB volume (control)
Number of subjects: 197
Study: 22453111

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A 100 U
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A 150 U
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Repeat onabotulinum toxin A injections (both doses)
Number of subjects: 60
Study: 19207293

Group type: EXPERIMENTAL
Intervention: sTfR levels (3.50 +/- 0.07 mg/l)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: sTfR quartiles
Number of subjects: 560

Group type: COMPARATOR
Intervention: Ferritin levels
Number of subjects: 560
Study: 16225965

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recent condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-famous names
Number of subjects: 30
Study: 12051211

Group type: EXPERIMENTAL
Intervention: Immediate referral for lumbar spine x-ray
Number of subjects: 659

Group type: COMPARATOR
Intervention: No referral for lumbar spine x-ray
Number of subjects: 659
Study: 10730561

Group type: EXPERIMENTAL
Intervention: Interferon alpha plus ketoprofen (group B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Interferon alpha plus ribavirin (group C)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Interferon alpha alone (group A)
Number of subjects: 49
Study: 7489418

Group type: EXPERIMENTAL
Intervention: Combination of plain bupivacaine with buprenorphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 30
Study: 1934866

Group type: EXPERIMENTAL
Intervention: Caffeine 1 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 2 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 4 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 8
Study: 6283800

Group type: EXPERIMENTAL
Intervention: Fibre rich breakfast (whole grain bread and whole apples, 8.4 g dietary fibre)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fibre poor breakfast (white bread and apple juice, 3.1 g dietary fibre)
Number of subjects: 8
Study: 6360415

Group type: EXPERIMENTAL
Intervention: Cholestyramine plus diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 0
Study: 30119663

Group type: EXPERIMENTAL
Intervention: Flap fixation using ARTISS tissue glue with a low suction drain
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Flap fixation using sutures and a low suction drain
Number of subjects: 336

Group type: COMPARATOR
Intervention: Conventional wound closure (without flap fixation) and low suction drainage
Number of subjects: 336
Study: 27496149

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 46
Study: 25225241

Group type: EXPERIMENTAL
Intervention: History of AFib
Number of subjects: 4120

Group type: COMPARATOR
Intervention: No history of AFib
Number of subjects: 4120
Study: 23134880

Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling and education about regular foods (group 1)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Dietary supplements and usual diet (group 2)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual diet without individualized counseling (group 3)
Number of subjects: 111
Study: 20155838

Group type: EXPERIMENTAL
Intervention: Combination antibiotics (doxycycline and rifampin)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination antibiotics
Number of subjects: 42
Study: 17644537

Group type: EXPERIMENTAL
Intervention: Simple Erosion Narrowing Score (SENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sharp-van der Heijde Score (SHS)
Number of subjects: 0
Study: 15779531

Group type: EXPERIMENTAL
Intervention: Judged probability of a target cause when competing displayed causes have low support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judged probability of a target cause when competing displayed causes have high support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency estimation task for target causes
Number of subjects: 0
Study: 12768894

Group type: EXPERIMENTAL
Intervention: Combination of 4% sodium chondroitin sulfate and 3% sodium hyaluronate
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 1.4% sodium hyaluronate
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 3% hyaluronate
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 156
Study: 10627795

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10172394

Group type: EXPERIMENTAL
Intervention: Caudal epidural block with 1.2 mL/kg of 0.25% bupivacaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Local infiltration with ilioinguinal/iliohypogastric block
Number of subjects: 24
Study: 2025147

Group type: EXPERIMENTAL
Intervention: Low-intensity treatment (self-help booklet and 20-30 minute session with a trained counselor)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: High-intensity treatment (low-level treatments plus individually tailored follow-up treatments)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control (informational leaflet on smoking)
Number of subjects: 466
Study: 7469210

Group type: EXPERIMENTAL
Intervention: Minocycline, 100 mg once or twice daily for 7 or 21 days
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 289
Study: 30904540

Group type: EXPERIMENTAL
Intervention: Intrastromal voriconazole (ISV) injection
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topical natamycin alone
Number of subjects: 70
Study: 29150209

Group type: EXPERIMENTAL
Intervention: bOPV-IPV immunization schedules
Number of subjects: 1640
Study: 25479118

Group type: EXPERIMENTAL
Intervention: Video plus usual care (8-minute video depicting cardiopulmonary resuscitation)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care (standard pamphlet and routine discussions)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 208
Study: 24147660

Group type: EXPERIMENTAL
Intervention: Double cerclage method
Number of subjects: 33

Group type: COMPARATOR
Intervention: Classic McDonald cerclage method
Number of subjects: 33
Study: 22226309

Group type: EXPERIMENTAL
Intervention: Homeopathy treatment (individualized homeopathic medicines in fifty millesimal (LM) potencies)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional treatment (including analgesics, antipyretics, and anti-inflammatory drugs)
Number of subjects: 81
Study: 19957840

Group type: EXPERIMENTAL
Intervention: Open-door cervical expansive laminoplasty (ELP) with anchor fixation (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional silk thread fixation (group B)
Number of subjects: 44
Study: 17570205

Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 18114

Group type: EXPERIMENTAL
Intervention: FS
Number of subjects: 18114

Group type: EXPERIMENTAL
Intervention: TC
Number of subjects: 18114
Study: 15030985

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin
Number of subjects: 1121

Group type: COMPARATOR
Intervention: peginterferon alfa‐2a plus placebo
Number of subjects: 1121

Group type: COMPARATOR
Intervention: interferon alfa‐2b plus ribavirin
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: sustained virological response
Number of subjects: 1121
Study: 12860733

Group type: EXPERIMENTAL
Intervention: Combined therapy with methotrexate (MTX) and sulfasalazine (SSZ) during the first year
Number of subjects: 146

Group type: COMPARATOR
Intervention: Single disease modifying antirheumatic drug treatment
Number of subjects: 146
Study: 10073394

Group type: EXPERIMENTAL
Intervention: Anticonvulsants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study: 8541274

Group type: EXPERIMENTAL
Intervention: Locust-bean (Ceratonia siliqua) gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary fibre from lupin (Lupinus albus) and insoluble maize-cob fibre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locust-bean gum
Number of subjects: 0
Study: 1742915

Group type: EXPERIMENTAL
Intervention: PRP vaccine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 101
Study: 7096149

Group type: EXPERIMENTAL
Intervention: 30-min treadmill run at 60% VO2 max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 30-min treadmill run at 80% VO2 max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 30-min treadmill run at self-selected pace
Number of subjects: 6

Group type: COMPARATOR
Intervention: 30 min rest (control experiment)
Number of subjects: 6
Study: 30123586

Group type: EXPERIMENTAL
Intervention: Stimulation of quadriceps (QG, n=24)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (CG, n=26)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Stimulation of diaphragm (DG, n=17)
Number of subjects: 67
Study: 26857391

Group type: EXPERIMENTAL
Intervention: Ultramicronized Palmitoylethanolamide (um-PEA) added to IFN-β1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24612546

Group type: EXPERIMENTAL
Intervention: AST1306 at 1000 mg BID
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: AST1306 at 1500 mg BID
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: AST1306 at 800 mg TID
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: AST1306 at 1200 mg TID
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: AST1306 (various doses)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: AST1306 under fed conditions
Number of subjects: 71
Study: 23271159

Group type: EXPERIMENTAL
Intervention: SMS Turkey intervention group (text messaging-based smoking cessation program)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Brochure control group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: SMS Turkey intervention group (female participants)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Brochure control group (female participants)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: SMS Turkey intervention group (light smokers)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Brochure control group (light smokers)
Number of subjects: 151
Study: 19880790

Group type: EXPERIMENTAL
Intervention: rhIGF-I (40, 80, or 120 microg/kg, administered sc, twice daily)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (observed, n = 25)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: rhIGF-I (120 microg/kg)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: rhIGF-I treatment
Number of subjects: 136
Study: 17390422

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dyclonine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 15604947

Group type: EXPERIMENTAL
Intervention: Manual ROI techniques
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Semi-automatic ROI techniques
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mirror technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Measurement of fractional change during treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Conversion of quantitative methods to measure fractional change
Number of subjects: 20
Study: 12020483

Group type: EXPERIMENTAL
Intervention: PTMR plus maximal medical therapy (MMT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: MMT only
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: PTMR plus MMT
Number of subjects: 141
Study: 9665202

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) maintenance treatment at a starting dose of 3 mU/m2 three times per week.
Number of subjects: 92

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) maintenance treatment.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Interferon alpha (IFN) maintenance treatment and No treatment (control group).
Number of subjects: 92
Study: 7864608

Group type: EXPERIMENTAL
Intervention: 10% fructose with 3% soluble fibre and 1% insoluble fibre preload
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Preload (any type)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fructose/fibre or placebo
Number of subjects: 24
Study: 2681410

Group type: EXPERIMENTAL
Intervention: Felodipine conventional (5 mg twice a day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Felodipine extended release (10 mg once daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Felodipine conventional and extended release
Number of subjects: 19
Study: 4479277

Group type: EXPERIMENTAL
Intervention: High-volume feeds (230 ml/kg/day of S.M.A. S26 milk)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional feeds (180 ml/kg/day of S.M.A. S26 milk)
Number of subjects: 5
Study: 31860387

Group type: EXPERIMENTAL
Intervention: PQQ (20 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (PQQ and PLC)
Number of subjects: 23
Study: 30844949

Group type: COMPARATOR
Intervention: PEEPARDSNET (13 ± 1 cm H2O)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PEEPINCREMENTAL (22 ± 3 cm H2O)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PEEPDECREMENTAL (21 ± 4 cm H2O)
Number of subjects: 14
Study: 29234749

Group type: EXPERIMENTAL
Intervention: 50% autogenous bone mixed with 50% anorganic bovine bone (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 100% anorganic bovine bone (group B)
Number of subjects: 32
Study: 26790796

Group type: EXPERIMENTAL
Intervention: Periarticular mixture of drugs (bupivacaine, ketorolac, morphine, adrenaline)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 80
Study: 23452753

Group type: EXPERIMENTAL
Intervention: CANSAS-C (Clinician-rated)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: CANSAS-P (Patient-rated)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: HAS-C (Clinician-rated)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: HAS-P (Patient-rated)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: CANSAS and HAS-C
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: CANSAS
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: HAS
Number of subjects: 605
Study: 21547879

Group type: EXPERIMENTAL
Intervention: Sodium Phosphate (NaP)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: colonLYTLEY (PEG)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Picoprep (Pico)
Number of subjects: 634
Study: 18675179

Group type: EXPERIMENTAL
Intervention: Collaborative investigator-initiated clinical research in critical care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised-controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing collaboration between research groups
Number of subjects: 0
Study: 17245476

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (e.g., pioglitazone)
Number of subjects: 0
Study: 14512874

Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) monotherapy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Interferon alfa (IFN-alpha) monotherapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 10710050

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 32
Study: 10436945

Group type: EXPERIMENTAL
Intervention: Nilestrioli 2 mg twice a month and Perphenazine 12 mg and Doxepin 75 mg per day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tolfenamic acid 300 mg a day
Number of subjects: 80
Study: 7955699

Group type: EXPERIMENTAL
Intervention: Modified Keller-Lelievre operation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Original Keller-Lelievre technique
Number of subjects: 35
Study: 2956874

Group type: EXPERIMENTAL
Intervention: Oral enoximone (150 mg 3 times daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous enoximone (0.75 mg/kg)
Number of subjects: 17
Study: 31396995

Group type: EXPERIMENTAL
Intervention: PBK-1701TC (320 mg simethicone)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Oral sulfate solution (OSS)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: PBK-1701TC
Number of subjects: 224
Study: 28743135

Group type: EXPERIMENTAL
Intervention: Microsurgical treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 21
Study: 29262825

Group type: EXPERIMENTAL
Intervention: CCOT (Curcuminoids extract, hydrolyzed collagen and green tea extract)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (experimental diet without CCOT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CCOT
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 26418341

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg twice-daily plus Vitamin D3 1,000 IU twice-daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 23801725

Group type: EXPERIMENTAL
Intervention: Low-saturated-fat dietary counseling
Number of subjects: 518

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 518
Study: 21669891

Group type: EXPERIMENTAL
Intervention: Specialized care group with brief physician training and computer-assisted medication management
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment-as-usual group
Number of subjects: 24
Study: 18952455

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 141

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 141
Study: 16776387

Group type: EXPERIMENTAL
Intervention: Access to automated patient registries and semi-automated clinical measure reports; five sites received computerized clinical reminders; three one-day learning sessions conducted.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Three one-day learning sessions conducted.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Shortened learning sessions and incorporation of health information technology.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cost per site.
Number of subjects: 9
Study: 15312348

Group type: EXPERIMENTAL
Intervention: Vp‐16 1000 mg/m(2) with rhG‐CSF 300 microg.body(‐1).day(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vp‐16 1500 mg/m(2) with rhG‐CSF 300 microg.body(‐1).day(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison group receiving different Vp‐16 dosage)
Number of subjects: 30